Latest Issue
Advertisement
The meeting had more than 2,500 registrants attending in person or online.
JZP458, which is approved in the United States and Canada, is a new Erwinia-derived asparaginase.
The retrospective, observational study included adults who received their first allogeneic HSCT during their first remission.
Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ...
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint.
Advertisement
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase.
The application for the approval of epcoritamab is based on results from the phase I/II EPCORE NHL-1 trial.
The supplemental BLA submission is supported by data from the CARTITUDE-4 study.
The FDA has put a clinical hold on the investigational new drug CART-ddBCMA.
Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia.
Dose reduction may be a strategy to mitigate the risk of cardiac AEs from recurring or worsening in B-cell malignancies.
Luspatercept-aamt demonstrated “favorable outcomes” compared with epoetin alfa across common mutations in MDS.
The estimated seven-year EFS rate was 76.7% in patients receiving rituximab maintenance.
Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A.
Exposure to thalidomide analogs is associated with TP53 mutations in patients with therapy-related myeloid neoplasms.
Given the multitude of novel therapies recently approved, clinicians must consider how to best sequence the options.
CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.